2023
The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness
Feikin D, Karron R, Saha S, Sparrow E, Srikantiah P, Weinberger D, Zar H. The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness. The Lancet Infectious Diseases 2023, 24: e318-e327. PMID: 38000374, DOI: 10.1016/s1473-3099(23)00568-6.Peer-Reviewed Original ResearchLower respiratory tract infectionsRespiratory syncytial virusRSV diseaseRespiratory illnessSyncytial virusRespiratory diseaseAcute lower respiratory tract infectionPrevention of RSVAcute respiratory illnessRespiratory tract infectionsImportant public health benefitsInappropriate antibiotic useSevere respiratory illnessCause infant mortalityCost-effective interventionPublic health benefitsHealth care systemMaternal vaccinesRecurrent hospitalisationsRSV preventionSecondary pneumoniaTract infectionsMiddle-income countriesLung healthAntibiotic use
2019
P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease
McGuire D, Zinman B, Inzucchi S, Anker S, Wanner C, Kaspers S, Von Eynatten M, Johansen O, Elsasser U, Pocock S, Fitchett D, Jamal W, Hantel S, Lund S. P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease. European Heart Journal 2019, 40: ehz746.0869. DOI: 10.1093/eurheartj/ehz746.0869.Peer-Reviewed Original ResearchEMPA-REG OUTCOME trialEffect of empagliflozinCause hospitalisationType 2 diabetesHospitalisation eventsOutcome trialsHeart failureCardiovascular diseaseMajor adverse CV eventsTotal burdenAdjusted hazard ratioAdverse CV eventsAtherosclerotic cardiovascular diseaseCox regression modelStandard of careEvent rate ratioCV deathCV eventsEmpagliflozin groupPlacebo patientsRecurrent hospitalisationsCV diseasePlacebo groupFirst eventHazard ratio
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply